HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Natalie Dimier Selected Research

glofitamab

1/2022Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
1/2021Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Natalie Dimier Research Topics

Disease

4Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022 - 08/2016
4Basal Cell Carcinoma (Rodent Ulcer)
01/2019 - 01/2017
1Neoplasms (Cancer)
01/2022
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2021
1Primary Myelofibrosis (Myelosclerosis)
01/2018
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2018
1Residual Neoplasm
01/2018
1Disease Progression
01/2017
1Thrombocytopenia (Thrombopenia)
08/2016
1Neutropenia
08/2016

Drug/Important Bio-Agent (IBA)

4HhAntag691IBA
01/2019 - 01/2017
2glofitamabIBA
01/2022 - 01/2021
2Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2018
2obinutuzumabIBA
02/2017 - 08/2016
2Rituximab (Mabthera)FDA Link
02/2017 - 08/2016
2Bendamustine HydrochlorideFDA Link
02/2017 - 08/2016
1ruxolitinibIBA
01/2018
1Janus Kinase InhibitorsIBA
01/2018

Therapy/Procedure

1Therapeutics
08/2016